ERBB2 and neoplasm: Daily oral administration of SLC-0111 to mice harboring MDA-MB-231 LM2-4 orthotopic human breast tumors (known to be ER/PR and HER2 negative, CAIX-positive) resulted in significant, dose-dependent reductions in tumor growth [34].